Evidence map›Paper›PMID 22374940›Full record

ArticleCancer prevention research (Philadelphia, Pa.)2012

Carnosol, a constituent of Zyflamend, inhibits aryl hydrocarbon receptor-mediated activation of CYP1A1 and CYP1B1 transcription and mutagenesis.

Arash Mohebati, Joseph B Guttenplan, Amit Kochhar, Zhong-Lin Zhao, Wieslawa Kosinska, Kotha Subbaramaiah, Andrew J Dannenberg

RetractedAbstract readRetracted Publication
In one paragraph

Article in Cancer prevention research (Philadelphia, Pa.), 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
2.0field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 37 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Molecules (Basel, Switzerland) · 2022
    Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Modulation of benzo[a]pyrene-DNA adduct formation by CYP1 inducer and inhibitor.Genes and environment : the official journal of the Japanese Environmental Mutagen Society · 2017
    Review
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. CYP1A1 regulates breast cancer proliferation and survival.Molecular cancer research : MCR · 2013
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 1 country.

Arash MohebatiDepartment of Surgery (Head and Neck Service), Memorial Sloan-Kettering Cancer Center, New York, New York, USA.
Joseph B Guttenplan
Amit Kochhar
Zhong-Lin Zhao
Wieslawa Kosinska
Kotha Subbaramaiah
Andrew J Dannenberg
New York University · USCornell University · USJohns Hopkins University · USMemorial Sloan Kettering Cancer Center · US

Funding

RESEARCH TRAINING IN OTOLARYNGOLOGYT32DC000027 · NIDCD · JOHNS HOPKINS UNIVERSITY · PI CAREY, JOHN PATRICK · 1989 to 2023
$5.5M
HEAD AND NECK TRAINING PROGRAM SURGICAL ONCOLOGYT32CA009685 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI FAGIN, JAMES A, WONG, RICHARD J · 1992 to 2022
$3.6M
NCI NIH HHS T32 CA009685NCI NIH HHS T32 CA09685NIDCD NIH HHS T32 DC000027PHS HHS T32 000027
6 · The paper itself

Abstract

The aryl hydrocarbon receptor (AhR), a ligand-activated member of the basic helix-loop-helix family of transcription factors, plays a significant role in polycyclic aromatic hydrocarbon (PAH)-induced carcinogenesis. In the upper aerodigestive tract of humans, tobacco smoke, a source of PAHs, activates the AhR leading to increased expression of CYP1A1 and CYP1B1, which encode proteins that convert PAHs to genotoxic metabolites. Inhibitors of Hsp90 ATPase cause a rapid decrease in levels of AhR, an Hsp90 client protein, and thereby block PAH-mediated induction of CYP1A1 and CYP1B1. The main objective of this study was to determine whether Zyflamend, a polyherbal preparation, suppressed PAH-mediated induction of CYP1A1 and CYP1B1 and inhibited DNA adduct formation and mutagenesis. We also investigated whether carnosol, one of multiple phenolic antioxidants in Zyflamend, had similar inhibitory effects. Treatment of cell lines derived from oral leukoplakia (MSK-Leuk1) and skin (HaCaT) with benzo[a]pyrene (B[a]P), a prototypic PAH, induced CYP1A1 and CYP1B1 transcription, resulting in enhanced levels of message and protein. Both Zyflamend and carnosol suppressed these effects of B[a]P. Notably, both Zyflamend and carnosol inhibited Hsp90 ATPase activity and caused a rapid reduction in AhR levels. The formation of B[a]P-induced DNA adducts and mutagenesis was also inhibited by Zyflamend and carnosol. Collectively, these results show that Zyflamend and carnosol inhibit Hsp90 ATPase leading to reduced levels of AhR, suppression of B[a]P-mediated induction of CYP1A1 and CYP1B1, and inhibition of mutagenesis. Carnosol-mediated inhibition of Hsp90 ATPase activity can help explain the chemopreventive activity of herbs such as Rosemary, which contain this phenolic antioxidant.

Indexed as

DNA AdductsMutagenesisTranscription, GeneticAbietanesAnticarcinogenic AgentsAntioxidantsAryl Hydrocarbon HydroxylasesBenzo(a)pyreneCell Line, TumorCytochrome P-450 CYP1A1Cytochrome P-450 CYP1B1HSP90 Heat-Shock ProteinsHumansLigandsPlant ExtractsReceptors, Aryl HydrocarbonAbietanesAnticarcinogenic AgentsAntioxidantsAryl Hydrocarbon HydroxylasesBenzo(a)pyrenecarnosolCYP1B1 protein, humanCytochrome P-450 CYP1A1Cytochrome P-450 CYP1B1DNA AdductsHSP90 Heat-Shock ProteinsLigandsPlant ExtractsReceptors, Aryl HydrocarbonZyflamend

Identifiers

PMID22374940
PMCPMC3324618
OpenAlexW2124644591

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.